I-Corps: Redox and pH responsive MRI contrast agents based on iron and cobalt

I-Corps：基于铁和钴的氧化还原和 pH 响应 MRI 造影剂

• 批准号: 1565070
• 负责人: Janet Morrow
• 金额: $ 5万
• 依托单位: SUNY at Buffalo
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-12-01 至 2016-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1565070&HistoricalAwards=false
• 关键词: Corps; Redox; pH; responsive; MRI

Magnetic resonance imaging (MRI) is a clinically important diagnostic procedure, with about half of MRI scans using contrast agents in order to better image differences in tissue. This project will involve the development and initial steps towards commercialization of contrast agents based on iron and cobalt as inexpensive and earth abundant elements. These new contrast agents are unique in that they are designed to switch on in tissue which has characteristics of a disease state. The responsive properties of these contrast agents could be extremely useful for improved diagnostics and treatment. This project will explore the potential of these agents for use in different diseases including cancer and brain injury. The team of three (academic PI, entrepreneurial lead and business mentor) will interview radiologists, medical doctors, insurance company representatives, MRI scanner manufacturers and MRI technicians to determine the factors that go into the development and marketing of new contrast agents. With support from the I-CORPS program, a team has been assembled to investigate the potential commercialization of magnetic resonance imaging contrast agents based on iron(II)/iron(III) and cobalt(II). The contrast agents are paramagnetic metal ion complexes that produce signal through chemical exchange saturation transfer (paraCEST). The proposed paraCEST agents are coordination complexes that can be tuned for redox potential and spin state. Furthermore, paraCEST agents generally produce contrast which is pH and temperature responsive. The proposed project will explore the possibility of commercializing these new contrast agents for 1) diagnosis of extent of tumor hypoxia as well as extracellular pH and 2) mapping traumatic brain injury which is thought to involve the production of reactive oxygen species and to affect redox status of tissue. The team will study the factors that go into making decisions on the commercialization of contrast agents and new diagnostic procedures by interviewing medical doctors, radiologists, MRI company representatives, and insurance company representatives. Potential outcomes include a refined focus on the development of contrast agents for new diagnostic procedures, a business plan for proceeding with the commercialization of the agents, as well as new collaborations and networks. Commercialization of these contrast agents may create new jobs towards meeting the long term goal of substituting current technologies that use rare earth elements of limited supply.

磁共振成像（MRI）是一种临床上重要的诊断程序，使用造影剂的MRI扫描中有大约一半，以便更好地在组织中图像差异。 该项目将涉及基于铁和钴作为廉价和地球丰富元素的对比剂商业化的开发和初步步骤。 这些新的对比剂的独特之处在于它们旨在在具有疾病状态的特征的组织中打开。 这些对比剂的响应性能对于改善诊断和治疗可能非常有用。该项目将探索这些药物在包括癌症和脑损伤在内的不同疾病中使用的潜力。 由三个组成的团队（PI，企业家负责人和商业导师）将采访放射科医生，医生，保险公司代表，MRI扫描仪制造商和MRI技术人员，以确定新的对比代理的开发和营销因素。 在I-Corps计划的支持下，已经组装了一个团队，以研究基于铁（II）/铁（III）和钴（II）的磁共振成像对比剂的潜在商业化。 对比剂是通过化学交换饱和转移（Paracest）产生信号的顺磁金属离子复合物。 所提出的Paracest Agent是可以调节氧化还原电位和自旋状态的协调配合物。 此外，最有偏的药物通常会产生对比度，即pH值和温度响应。 拟议的项目将探索将这些新的对比剂商业化的可能性，以诊断肿瘤缺氧程度以及细胞外pH和2）绘制创伤性脑损伤的可能性，这被认为涉及活性氧的产生并影响组织的氧化还原状态。 该团队将通过采访医生，放射科医生，MRI公司代表和保险公司代表来研究对对比代理商和新诊断程序商业化的决定的因素。 潜在的结果包括针对新诊断程序的对比代理的开发，一项针对代理商商业化的业务计划以及新的合作和网络。 这些对比代理商的商业化可能会创造新的就业机会，以实现替代使用有限供应的稀土元素的当前技术的长期目标。